Uncategorized

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023

GenSight Biologics announces that efficacy and safety data from patients with Leber Hereditary Optic Neuropathy carrying the ND4 mutation treated with lenadogene nolparvovec through early access programs, were presented at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society.

GenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023 Read More »

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Tango Therapeutics, Inc. announced the acceptance of two oral and two poster presentations at the American Association for Cancer Research 2023 Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting Read More »

Scroll to Top